Jing Qiang
Voorzitter bij Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Vermogen: 17 M $ op 31-05-2024
Profiel
Jing Qiang is currently the Chairman of Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Prior to this, he worked as a Non-Executive Director at Sinomab Bioscience Ltd.
from 2020 to 2021.
From 2010 to 2018, he was a Managing Director at China International Capital Corp.
Ltd.
and before that, he worked as a Research Analyst at China International Capital Corp.
Ltd.
(Broker).
Mr. Qiang received his undergraduate degree from Shanghai Jiao Tong University in 2005 and his graduate degree from Fudan University in 2010.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SINOMAB BIOSCIENCE LTD.
6.67% | 31-01-2024 | 72 823 636 ( 6.67% ) | 17 M $ | 31-05-2024 |
Actieve functies van Jing Qiang
| Bedrijven | Functie | Begin |
|---|---|---|
Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
 Suzhou Sinovent Pharmaceutical Technology Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China. | Voorzitter | - |
Eerdere bekende functies van Jing Qiang
| Bedrijven | Functie | Einde |
|---|---|---|
| SINOMAB BIOSCIENCE LIMITED | President | 30-11-2020 |
| CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED | Algemeen Directeur | 01-03-2018 |
China International Capital Corp. Ltd. (Broker)
 China International Capital Corp. Ltd. (Broker) Investment Banks/BrokersFinance China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China. | Analyst-Equity | - |
Opleiding van Jing Qiang
| Shanghai Jiao Tong University | Undergraduate Degree |
| Fudan University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SINOMAB BIOSCIENCE LIMITED | Health Technology |
| CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED | Finance |
| Bedrijven in privébezit | 2 |
|---|---|
Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Suzhou Sinovent Pharmaceutical Technology Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China. | Commercial Services |
China International Capital Corp. Ltd. (Broker)
China International Capital Corp. Ltd. (Broker) Investment Banks/BrokersFinance China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China. | Finance |
